Related Experiment Video
Updated: Jul 16, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
Application of thermo-responsive polymers as an enema formulation for the treatment of ulcerative colitis
Ena Hattanda1, Narumi Maida1, Kaoru Hirose1
1Faculty of Pharmaceutical Sciences, Tokyo University of Science, 6-3-1 Niijuku, Katsushika, Tokyo 125-8585, Japan.
Abstract:
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by abdominal pain and diarrhea. Although 5-aminosalicylic acid (5-ASA) enemas are widely used, conventional formulations can result in rectal leakage and poor retention, substantially impairing the therapeutic efficacy and quality of life (QOL) of patients. To address these limitations, in this study, we developed a thermoresponsive and mucoadhesive dual-functionality enema system by combining poloxamer with carbopol (CP). This study optimized a thermoresponsive and mucoadhesive rectal gel formulation for 5-ASA and evaluated its physicochemical properties and therapeutic efficacy in experimental ulcerative colitis. The formulation exhibited a gelation temperature of 30-35 °C, indicating its suitability for situ gel formation in the colon. The 1H NMR analysis confirmed minimal interactions between 5-ASA and the polymers. Increasing the CP concentration markedly delayed drug release, likely due to enhanced network entanglement within the gel. Ex vivo evaluation using porcine colonic mucosa indicated reduced leakage and improved adhesion compared with a commercial formulation. Furthermore, in vitro studies using Caco-2 cells showed enhanced retention of the active compounds. These findings indicate that the proposed system enables injectable administration, in situ gelation, strong mucosal adhesion, and gradual release of 5-ASA while maintaining enhanced mucoadhesion and rectal retention, thereby improving retention and therapeutic potential. Furthermore, the administration of the formulation to rats with UC led to a significantly higher anti-inflammatory effect. Thus, the developed approach represents a promising strategy for enhancing treatment efficacy and patient compliance in ulcerative colitis.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Oral Drug Delivery Systems: Delayed-Release Systems